Thrombosis

Thrombosis is a life-threatening condition in which abnormal clot formation disrupts blood flow, leading to heart attack, stroke, deep vein thrombosis (DVT), and pulmonary embolism (PE). GemPharmatech's comprehensive portfolio of arterial, venous, and genetically modified thrombosis models targets distinct clot formation mechanisms, supporting preclinical evaluation of antiplatelet and anticoagulant therapies.

5
Validated Models
40+
Studies Completed
10
IND-Enabling Studies

Advantages

Our Advantages

Industry-leading capabilities for thrombosis research

Diverse Thrombosis Models

Arterial, venous, and genetic models that replicate distinct clinical thrombotic disease scenarios.

Clinical Translation and Physiological Relevance

Closely reflect clinical disease to support translational research.

Genetic Diversity for Drug Screening

Various strains to mimic human coronary heart disease for drug screening.

Preclinical Expertise & IND Support

Extensive experience in thrombotic drug efficacy studies, with drug types including antibodies, small molecules, and small nucleic acids;

Model Library

Comprehensive thrombosis models for preclinical research

Case Studies

Case Studies & Validation Data

Explore our validated thrombosis studies demonstrating the efficacy of various therapeutic interventions.

FeCl₃ Induced Carotid Arterial Thrombosis

Ticagrelor inhibits FeCl₃-induced thrombosis in mice

Learn more

(A) Study design. (B-D) Ticagrelor treatment significantly maintained blood flow (B), prolonged time to vessel occlusion (C), and reduced maximum blood flow blockade (D) versus control.

Abelacimab Inhibits Thrombosis Dose-dependently.

Learn more

(A) Carotid blood flow after FeCl₃ injury. Abelacimab (0.125-0.5 mpk) delayed flow cessation vs. FeCl₃ only control. (B) Time to occlusion was dose-dependently prolonged. (C) APTT was significantly increased, confirming anticoagulation. Data as mean±SEM; *p<0.05, p<0.01,**p<0.0001.

Abelacimab Reduces Thrombus Burden

Learn more

H&E-stained carotid artery sections post FeCl₃ injury. Vehicle control shows occlusive thrombus. Increasing Abelacimab doses (0.125, 0.25, 0.5 mg/kg) progressively and dose-dependently reduced thrombus size. The highest dose (0.5 mg/kg) resulted in only a small, non-occlusive thrombus, preserving lumen patency.

PCR-MCAO Stroke

Vascular imaging and pathology post-laser injury.

Learn more

(A) Time-course vascular imaging (0, 5, 10 min) with/without fluorescence promotion (Rb+, Rb-). Maximum intensity projections (right) visualize vascular network architecture and blood flow signal. (B) Pathological exam at 6h. Specimen photos (red circles mark laser site) and TTC stained sections show infarction area after MCAO modeling.

All Product

All Product Lines

Browse our comprehensive catalog of over 30,000 mouse models covering various gene families, signaling pathways, and disease models. Use advanced filters to find the perfect model for your research.